Neos Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Neos Therapeutics Inc (NEOS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Neos Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 57M vs 141M combined for its competitors (28.9% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-12.2% annualized vs trailing 12 months).
- Peer revenue share: Neos Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 0.9% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NEOS Sales vs. its Competitors, Q3 2018
Neos Therapeutics Inc generated 100.00 % of the combined sales of its peer group, up from 0.93 % a year earlier.
API endpoints for this dataset
Neos Therapeutics Inc vs. its Competitors, Q3 2018
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Neos Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Neos Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Neos Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Neos Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 86.8% for Neos Therapeutics Inc. Neos Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Neos Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Neos Therapeutics Inc | No | No | No | Yes |
| Competitors combined (2) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NEOS Stock Performance relative to its Competitors
NEOS Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Zevra Therapeutics Inc | 282.9% | Outperformed |
| 2 | Regencell Bioscience Holdings Limited | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Neos Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Neos Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Neos Therapeutics Inc |
57.22 | 56.99 |
 Regencell Bioscience Holdings Limited |
2,443.34 | 3,068.30 |
 Zevra Therapeutics Inc |
560.53 | 140.55 |
| SUBTOTAL | 3,061.09 | 3,265.84 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Neos Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Neos Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Neos Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zevra Therapeutics Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
Company report basis, confidence, active dates and source counts for Neos Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Neos Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Zevra Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Neos Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Neos Therapeutics Inc | 57 | - | - |
| Regencell Bioscience Holdings Limited | 2,443 | 15,189,604 | -57,930 |
| Zevra Therapeutics Inc | 561 | 2,304,066 | 1,273,049 |
| PEERS TOTAL | 3,004 | 12,200,943 | 250,776 |
Neos Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (447 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.57 % | 38.19 % (avg) | -37.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.52 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 1.08 % | 7.48 % (avg) | -6.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Neos Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.2x | - |
| EV / EBITDA | - | 15.2x | - |
| P/B | -2.4x | 4.2x | -6.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.68 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Neos Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue Growth | 173.30 % | 99.81 % | 29.33 % |
| Operating Margin | - | -87.01 % | -16.11 % |
| Return on Invested Capital | -61.65 % | -145.80 % | -25.54 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Neos Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.08 % vs industry average 7.48 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Neos Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Neos Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-12.2% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Neos Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Neos Therapeutics Inc | 0.27 | 0.83 | - |
| Regencell Bioscience Holdings Limited | 10.75 | 10.77 | - |
| Zevra Therapeutics Inc | 2.41 | 5.28 | 0.08 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Neos Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Neos Therapeutics Inc | Q3 2018 | -28.5 % | - |
| Regencell Bioscience Holdings Limited | Q2 2025 | - | - |
| Zevra Therapeutics Inc | Q3 2026 | +44.9 % | - |
| PEERS TOTAL | +15.3 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Neos Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Neos Therapeutics Inc | Q3 2018 | -20.6 % | - |
| Regencell Bioscience Holdings Limited | Q2 2025 | - | - |
| Zevra Therapeutics Inc | Q3 2026 | -86.1 % | -57.0 % |
Neos Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Neos Therapeutics Inc | - | - | - |
| Regencell Bioscience Holdings Limited | - | - | - |
| Zevra Therapeutics Inc | 26.33% | 29.88% | 38.02% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Neos Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Neos Therapeutics Inc | - | 1.00 |
| Regencell Bioscience Holdings Limited | - | 0.80 |
| Zevra Therapeutics Inc | 7.38 | 3.99 |
| PEERS AVERAGE | 69.42 | 0.94 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.